Abstract：
Autoimmune haemolytic anaemia (AIHA), autoimmune destruction of erythrocytes is most commonly secondary to immunomodulated conditions. The association between AIHA and inflammatory bowel disease (IBD) has been poorly investigated. We aim to report a case of AIHA in a patient with ulcerative colitis (UC) treated with vedolizumab.A case of a woman in her 30s with UC that after the initiation of vedolizumab developed severe anaemia. Due to the absence of visible blood losses and a positive Coombs direct test, the diagnosis of AIHA was established. The patient initially initiated prednisolone with no response. Rituximab had to be introduced. After a few days with this therapy, there was a clinical and analytical improvement.AIHA must be taken into account as a possible cause of anaemia in patients with IBD. The differential diagnosis between IBD or drug-related (namely vedolizumab) as the cause of the AIHA is complex and almost impossible to establish.
摘要：
自身免疫性溶血性贫血（AIHA），红细胞的自身免疫破坏最常继发于免疫调节病症。AIHA与炎症性肠病（IBD）之间的关联研究很少。我们的目的是报告一例使用维多珠单抗治疗的溃疡性结肠炎（UC）患者的AIHA病例。一例30多岁的女性患有UC，在开始使用vedolizumab后出现严重贫血。由于没有可见的失血和Coombs直接测试阳性，AIHA的诊断得以确立。患者最初开始泼尼松龙，无反应。必须引入利妥昔单抗。经过几天的治疗，临床和分析有所改善.必须考虑AIHA作为IBD患者贫血的可能原因。作为AIHA的病因，IBD或药物相关（即维多珠单抗）之间的鉴别诊断是复杂的，几乎不可能建立。
